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Sarcopenia is among the most prevalent and serious cancer-related symptom, and is
strongly correlated with a poor prognosis. Moreover, it reportedly predicts poor prognosis
after surgery in patients with lung cancer. However, it is unclear whether sarcopenia directly
affects post-operative recurrence. The purpose of this study was to evaluate whether sarco-
penia can be a risk indicator for post-operative recurrence, and whether it suppresses anti-
tumor immunity, in a cohort of patients with resected non-small cell lung cancer.
Methods
This study retrospectively reviewed the data of 256 consecutive patients who underwent
curative lobectomy and lymph node dissection for non-small cell lung cancer at our institu-
tion. The psoas muscle mass index was calculated as the total psoas muscle area at the
third lumbar vertebral level/height2 (cm2/m2). Sarcopenia was defined by a psoas muscle
mass index of under 5.03 cm2/m2 and 3.17 cm2/m2 in male and female patients, respec-
tively. Post-operative prognosis and cumulative incidence of recurrence rates were
calculated.
Results
The 5-year overall survival and disease-free survival rates post-surgery were 59.5% and
38.6%, respectively, in patients with sarcopenia versus 81.1% and 72.1%, respectively, in
patients without sarcopenia (p < 0.001). The 5-year cumulative incidence of recurrence rate
in patients with sarcopenia was significantly higher than those without sarcopenia (49.9%
versus 22.4%, respectively) in every pathological stage. Pathological stages II and III (haz-
ard ratio, 3.36; p = 0.004), histological type (hazard ratio, 2.31; p = 0.025), and sarcopenia
(hazard ratio, 2.52; p = 0.001) were independent risk factors for post-operative recurrence
according to multivariate analysis.
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Conclusion
Sarcopenia is a risk indicator for post-operative recurrence in patients with non-small cell
lung cancer.
Introduction
Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths globally [1].
Although tumor characteristics, such as histology and TNM stage, and treatment factors, such
as surgery and chemotherapy, have traditionally been considered important to determine can-
cer prognosis, recently, patient factors like sarcopenia have started gaining attention [2]. Sig-
nificant loss of muscle (sarcopenia/cachexia) is among the most prevalent and serious cancer-
related symptoms and is strongly correlated to poor prognosis [2], especially in patients with
advanced cancer. Several studies have recently reported that sarcopenia in patients with resect-
able cancers including gastric cancer [3], colorectal cancer [4], pancreatic cancer [5], hepato-
cellular carcinoma [6], endometrial cancer [7], renal cell carcinoma [8], and lung cancer [9]
also contributes to poor post-operative survival. Poor prognosis in sarcopenic patients after
surgery may be attributed to two reasons. First, sarcopenia itself is generally accepted to confer
poor prognosis. Even if the cancer is completely cured through surgery, there is loss of skeletal
muscle mass and strength, resulting in physical disability and death [10]. Second, sarcopenia
may also contribute to the risk of cancer recurrence [10].
Skeletal muscle has recently been identified as a secretory organ, producing myokines;
these may activate immune cells to suppress the growth of cancer cells [11]. Although some
reports have demonstrated that sarcopenia decreases post-operative overall survival (OS)
[9,12–19] and disease-free survival (DFS) [9,14,18] in NSCLC patients, it is currently unclear
whether sarcopenia directly affects post-operative recurrence.
Therefore, the purpose of this study was to demonstrate whether sarcopenia can be a risk
indicator for post-operative recurrence, and to examine whether sarcopenia suppresses anti-
tumor immunity, in a cohort of patients with resected NSCLC.
Methods
Patients
This study was approved by the institutional review board of the Shiga University of Medical
Science (Approval Number: R2020-048). The need for informed consent was waived by the
institutional review board owing to the retrospective nature of the study. We accessed patients’
medical records between April, 2020 and June 2021. These records were all anonymized dur-
ing data collection; we used the anonymized data for our analysis.
This study reviewed the data of 256 consecutive patients who underwent curative lobec-
tomy and lymph node dissection for NSCLC at our institution between January 2011 and
December 2015. We collected data on the following patient characteristics: age, sex, perfor-
mance status, smoking history, adjuvant chemotherapy, maximum tumor size, short diameter
of lymph nodes which was maximum in mediastinum or hilar lymph nodes, pathological
stage, histological type, lymphocyte and monocyte pre-operative blood examination values,
and the cross-sectional area (cm2) of the psoas muscle at the third lumbar vertebral (L3) level
on computed tomography (CT) scans. Histological assessment was performed according to
the histological classification of the World Health Organization. The seventh edition of the
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TNM classification for lung cancer was used for pathological staging. Hematological data was
collected from each patient within two weeks prior to surgical treatment. We also recorded the
pre-operative lymphocyte-to-monocyte ratio (LMR), which was calculated by dividing the
absolute lymphocyte counts by the absolute monocyte counts. We used an LMR cut-off value
of 3.2, as previously reported [20,21]. We excluded the following cases: limited resection,
incomplete resection, and no CT image at the L3 level.
Definition of sarcopenia
We used the psoas muscle mass index (PMI), which had been reported by Hamaguchi et al. to
be a diagnostic tool for sarcopenia [22] and was often used in many reports to predict post-
operative outcomes in patients with NSCLC [9,16–18]. Preoperative CT scans were performed
within three months prior to surgery. The cross-sectional areas (cm2) of the right and left
psoas muscles at the L3 level were measured by manual tracing of CT data using Shade Quest
View R (Fujifilm, Japan). Subsequently, the total psoas area was normalized for height. The
PMI was calculated as previously described [22]: PMI = total psoas muscle area at the L3 level/
height2 (cm2/m2). Since no consensus currently exists on the PMI cut-off value of sarcopenia
to predict recurrence, we defined sarcopenia as a PMI of under 5.03 cm2/m2 in male patients
and 3.17 cm2/m2 in female patients. We derived these cut-off values to be good indicators for
recurrence. In predicting recurrence, this definition had a sensitivity of 67.2%, specificity of
57.1%, and area under the receiver operating characteristic curve value of 0.631 in males; in
comparison, those for females were 68.4%, 59.4%, and, 0.590, respectively (S1 Fig). In addition,
we created another group which included patients who underwent curative lobectomy and
lymph node dissection for NSCLC at our institution in 2016; this was the validation cohort. In
this cohort, we analyzed the association between sarcopenia and post-operative recurrence
using our PMI cut off values, and assessed the plausibility.
Post-operative outcomes
Post-operative outcomes were represented by the OS, DFS, and cumulative incidence of recur-
rence (CIR). OS was defined as the interval between the date of surgery and the date of death.
DFS was defined as the interval between the date of surgery and the date of death or cancer
recurrence (confirmed using an imaging test). CIR was defined as the interval between the
date of surgery and the date of cancer recurrence (confirmed using an imaging test) and was
set as the primary variable. Most patients were followed up postoperatively every three or six
months, until the fifth year after surgery. Screening examination included tumor markers,
chest and abdominal CT, and cerebellar magnetic resonance imaging. Bone scintigraphy and
positron emission tomography CT were performed on demand. The 5-year OS, DFS, and CIR
were compared between patients with and without sarcopenia.
Statistical analyses
Statistical analyses were performed using SPSS Statistics for Windows, version 25 (SPSS Inc.,
Chicago, IL, USA). Associations between variables were analyzed using Fisher’s exact test. The
t-test was also used to compare the means of parametric data between the two groups. The
Kaplan-Meier method was used to determine OS, DFS, and CIR. The log-rank test was used to
compare survival differences for each variable. The Cox’s proportional hazards model was
used for multivariate analysis. Statistically significant differences were defined as p< 0.05.
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Results
Patient characteristics
During the study period, 354 patients received surgery for NSCLC at our institution. Among
them, we excluded cases with limited and incomplete resections; 256 cases of curative lobec-
tomy and lymph node dissection were therefore included in this study. The median follow-up
period was 44.9 months. The patient characteristics are shown in Table 1. The mean age of
patients with sarcopenia were higher than those without, and there were no significant differ-
ences in the distribution of sarcopenia patients among various pathological stages. Adenocar-
cinomas were fewer and LMRs of ≦3.2 were more common in sarcopenia patients.
Survival and recurrence comparison between sarcopenia and non-
sarcopenia patients
The 5-year OS and DFS after surgery were 59.5% and 38.6%, respectively, in patients with sar-
copenia versus 81.1% and 72.1%, respectively, in patients without sarcopenia (p< 0.001)
(Fig 1). Since the direct influence of sarcopenia on cancer recurrence could not be estimated
using OS and DFS, we examined CIR. The 5-year CIR rate in patients with sarcopenia was
49.9%, which was significantly higher than the 22.4% observed in patients without sarcopenia
(Fig 2). Patients with and without sarcopenia were further divided according to pathological
stage. The 5-year CIR rate in patients with sarcopenia was higher in every stage than those
without sarcopenia (stage I: 29.8% in sarcopenia versus 5.5% in non-sarcopenia; p< 0.001,
stage II: 70.0% in sarcopenia versus 40.0% in non-sarcopenia; p = 0.030, stage III: 86.7% in sar-
copenia versus 56.1% in non-sarcopenia; p< 0.087) (Fig 3).
To assess the plausibility of our original PMI cut off values, we analyzed prognosis using the
validation cohort, which included 36 sarcopenia and 46 non-sarcopenia patients. The 5-year
OS and DFS after surgery were 77.9% and 50.2%, respectively, in patients with sarcopenia ver-
sus 88.0% and 66.5%, respectively, in patients without sarcopenia (S2 Fig). The 5-year CIR rate
was 48.0% in patients with sarcopenia versus 29.3% in patients without sarcopenia (S3 Fig).
Based on these results, we considered our PMI cut off values to be plausible, as we could dem-
onstrate the association between sarcopenia and post-operative recurrence in the validation
cohort.
Association between recurrence and clinicopathological factors
We identified the following potential risk factors for recurrence using the comparison between
sarcopenia and other factors commonly recognized to predict recurrence; these included: age
over 65 years, male sex, performance status 1–2, smoking history, absence of adjuvant chemo-
therapy, large tumor size, large lymph node size, pathological stage II and III, histological type
(other than adenocarcinoma and squamous cell carcinoma), grade of differentiation, lym-
phatic permeation, vascular invasion, sarcopenia, and low LMR (Table 2). According to multi-
variate analysis, pathological stage II and III (hazard ratio, 3.36; p = 0.004), histological type
(hazard ratio, 2.31; p = 0.025), and sarcopenia (hazard ratio, 2.52; p = 0.001) were independent
risk factors for post-operative recurrence (Table 3).
Discussion
In our cohort, sarcopenia was the risk indicator for post-operative recurrence in every stage.
Reports have previously demonstrated that sarcopenia decreased OS [9,12–19] and DFS
[9,14,18] after surgery in patients with NSCLC. In contrast to these previous studies, our study
has two unique features. First, using CIR, we are probably the first to demonstrate that
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Table 1. Characteristics of patients with and without sarcopenia.
Variables Sarcopenia Non-Sarcopenia p value
N = 128 % N = 128 %
Age, years 0.002
Median 70.1 - 66.9 -
Range 51–88 47–83
Sex 0.504
Male 89 69.5 84 65.6
Female 39 30.5 44 34.4
Performance status 0.062
0 96 75.0 108 84.4
1–2 32 25.0 20 15.6
Smoking history 0.070
(+) 100 78.7 88 68.8
(-) 27 21.3 40 31.2
Psoas mass index (Male) <0.001
Median 4.05 - 6.09 -
Range 1.97–5.02 5.03–8.58




� 3.2 36 28.1 23 18.0
> 3.2 92 71.9 105 82.0
Adjuvant chemotherapy (stage IB–III) 0.015
(+) 44 55.0 54 75.0
(-) 36 45.0 18 25.0
Tumor size (mm) 0.002
Median 30.9 - 23.8 -
Lymph node size 0.002
>1cm 29 22.7 11 8.6
≦1cm 99 77.3 117 91.4
Pathological stage
I 70 54.7 76 59.4 0.449
II 34 26.6 28 21.9 0.381
III 24 18.8 24 18.8 1.000
Histological type
Adenocarcinoma 78 60.9 95 74.2 0.023
Squamous cell carcinoma 35 27.3 24 18.8 0.103
Other 15 11.7 9 7.0 0.198
Grade of differentiation 0.125
1 47 38.2 53 48.2
2–4 76 61.8 57 51.8
Lymphatic permeation 0.401
(+) 71 59.2 64 53.8
(-) 49 40.8 55 46.2
Vascular invasion 0.019
(+) 91 75.8 70 58.8
(-) 29 24.2 49 41.2
LMR, lymphocyte-to-monocyte ratio.
https://doi.org/10.1371/journal.pone.0257594.t001
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sarcopenia in patients with lung cancer directly affected post-operative recurrence. We could
not determine whether sarcopenia directly affected cancer recurrence using OS or DFS,
because decreases in OS or DFS are not only attributable to lung cancer death/recurrence, but
also to deaths from other diseases. Indeed, sarcopenia itself is a poor prognostic factor, because
the loss of muscle mass and strength results in physical disability and death [10,23]. Second,
we focused on lobectomy as the surgical procedure. Previous studies showed heterogeneity in
the surgical procedures included, such as partial resection, segmentectomy, and pneumonec-
tomy; this could have affected the recurrence rate and prognosis.
We found sarcopenia to be an independent risk indicator for recurrence. Using multivari-
ate analysis, we compared the risk of recurrence using several factors that are commonly rec-
ognized to predict recurrence. We found that advanced pathological stage, histological type
(other than adenocarcinoma and squamous cell carcinoma), and sarcopenia were independent
risk factors for post-operative recurrence. Interestingly, the development of sarcopenia causes
a higher risk of recurrence than that of many tumor factors including histological type, grade
of differentiation, lymphatic permeation, and vascular invasion (Table 3).
There may be two reasons for the association between sarcopenia and post-operative recur-
rence. First, tumors in sarcopenia patients have higher malignant potential than those in
Fig 1. OS and DFS after surgery compared between sarcopenia patients and non-sarcopenia patients. DFS,
disease-free survival; OS, overall survival.
https://doi.org/10.1371/journal.pone.0257594.g001
Fig 2. CIR rate after surgery between sarcopenia patients and non-sarcopenia patients. CIR, cumulative incidence
of recurrence.
https://doi.org/10.1371/journal.pone.0257594.g002
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patients without sarcopenia. As a result, even if the pathological stages are equivalent, tumor
recurrence occurs more frequently in the former [13]. In the present study, NSCLC patients
with sarcopenia presented with larger tumor size, larger lymph node size, and more vascular
invasion than those without sarcopenia. Second, muscles exert a potential tumor inhibitory
effect via myokines; skeletal muscle has recently been identified as a secretary organ, and is
reported to activate immune cells [11]. To examine the association between sarcopenia and
pro-tumor/anti-tumor immunity, we used LMR, which can reflect the tumor suppressing
activity of tumor-infiltrating lymphocytes and the pro-tumor activity of macrophages in the
tumor microenvironment [20]. Therefore, an elevated LMR is favorable for anti-tumor immu-
nity, while a decrease favors pro-tumor immunity. In our study, post-operative recurrences
were significantly more common in patients with low LMR, and sarcopenia patients frequently
exhibited a low LMR. Previous studies have reported an association between decreased lym-
phocytes and sarcopenia. For example, a myokine, namely, interleukin (IL)-15 was reported to
have an important role in T cell proliferation [24]; exercise induces myokine IL-6, which
releases and activates natural killer cells, thereby reducing tumor growth [25]. Therefore, active
lymphocytes may be decreased in patients with sarcopenia, predisposing them to recurrences.
One study has reported an association between increasing monocytes and sarcopenia, where
the myokine irisin dampened macrophage activity in vitro [26]. Therefore, monocytes may
increase in patients with sarcopenia due to the decrease in irisin, leading to recurrence. It has
been reported that the peripheral monocyte count is associated with the density of the tumor-
associated macrophages; this is in turn associated with tumor progression and metastasis [27].
It is unclear whether therapeutic intervention for sarcopenia can prevent post-operative
recurrence. However, we believe that sarcopenia could be a treatment target to improve the
outcome of NSCLC patients who have undergone surgery. One of the therapeutic approaches
for sarcopenia is exercise. Chen et al. demonstrated that patients who engaged in exercise regu-
larly during the first six months after diagnosis have significantly higher OS and DFS (hazard
ratios: 0.62 and 0.39, respectively) [28]. Thus, cancer patients should not only exercise because
Fig 3. CIR rate after surgery between sarcopenia patients and non-sarcopenia patients divided according to their
pathological stages. CIR, cumulative incidence of recurrence.
https://doi.org/10.1371/journal.pone.0257594.g003
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Table 2. Association between CIR rate and clinicopathological factors.
Variables N CIR (%) p value
Patient factors
Age (years) 0.526
< 65 76 38.3














� 3.2 59 44.1
> 3.2 197 32.9
Treatment factors





>3cm 107 43.8 0.008
>5cm 40 55.2 < 0.001
Lymph node size
>1cm 40 52.6 0.010
Pathological stage
I 146 16.7 < 0.001
II, III 110 61.6 < 0.001
III 48 70.0 < 0.001
Histological type
Adenocarcinoma 173 31.7 0.021
Squamous cell carcinoma 59 36.1 0.600
Other 24 60.4 < 0.001
Grade of differentiation 0.003
1 100 25.6
2–4 133 45.4
Lymphatic permeation < 0.001
(+) 135 50.2
(-) 104 15.6
Vascular invasion < 0.001
(+) 161 47.3
(-) 78 11.3
CIR, cumulative incidence of recurrence; LMR, lymphocyte-to-monocyte ratio.
https://doi.org/10.1371/journal.pone.0257594.t002
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it improves their overall health, but because as a targeted approach it may improve sarcopenia
and decrease the risk of cancer recurrence.
There were several limitations to this study. First, this was a retrospective observational
study; some bias associated with the study design or analysis may therefore be inevitable. Sec-
ond, sarcopenia also occurs in patients suffering from malnutrition, congestive heart failure,
chronic obstructive pulmonary disease, chronic renal failure, etc. [23]. Therefore, we cannot
exclude the possibility that such potential confounders could have also increased sarcopenia in
our patients and influenced cancer recurrence. Third, the definition of sarcopenia varies
depending on different studies. Two main diagnostic tools have been proposed for sarcopenia;
one used muscle mass only, as reported by Prado et al. in 2008 [29], and one used the presence
of low gate speed, decreased grip strength, and low muscle mass, as reported by the European
Working Group on Sarcopenia in 2010 [23]. In our study, we used muscle mass to define sar-
copenia, because many studies have used this definition in predicting post-operative outcomes
in NSCLC patients. Furthermore, we used original cut-off values to define sarcopenia. There-
fore, the findings may not be generalized to other cut-off values or cohorts. To address this
issue, we analyzed the prognosis using our cut-off values in the validation cohort; this may be
considered plausible. Finally, LMR values may vary over time; therefore, we routinely collected
the hematological data from each patient within the two weeks before surgical treatment.
However, using only one set of hematological data may not offer adequate precision for assess-
ing post-operative prognosis.
Conclusion
In this study, sarcopenia was a risk indicator for post-operative recurrence in patients with
NSCLC. Our findings indicate the need for future translational research to clarify the biologi-
cal interaction between sarcopenia and regulation of cancer immunity.
Table 3. Multivariate analysis on cancer recurrence.
Variables HR 95% CI p value
Patient factors
Age ≧65 1.46 0.80–2.65 0.214
Gender Male 1.00 0.45–2.22 0.992
Performance status 1–2 0.60 0.30–1.23 0.166
Smoking history (+) 1.11 0.47–2.60 0.809
Sarcopenia (+) 2.52 1.48–4.28 0.001
LMR ≦3.2 0.97 0.85–1.10 0.593
Treatment factor
Adjuvant chemotherapy (-) 1.31 0.74–3.13 0.252
Tumor factors
Tumor size >5cm 1.26 0.66–2.40 0.478
Lymph node size >1cm 0.95 0.65–1.39 0.800
Pathological stage II, III 3.36 1.47–7.70 0.004
Pathological stage III 1.70 0.88–3.27 0.114
Histological type Other 2.31 1.11–4.82 0.025
Grade of differentiation 2–4 0.60 0.32–1.14 0.122
Lymphatic permeation (+) 1.78 0.84–3.74 0.131
Vascular invasion (+) 0.49 0.20–1.22 0.127
LMR, lymphocyte-to-monocyte ratio; HR, hazard ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0257594.t003
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Supporting information
S1 Fig. ROC curve for predicting recurrence using sarcopenia. ROC, receiver operating
characteristic.
(TIF)
S2 Fig. OS and DFS after surgery compared between sarcopenia patients and non-sarcope-
nia patients in the validation cohort. DFS, disease-free survival; OS, overall survival.
(TIF)
S3 Fig. CIR rate after surgery between sarcopenia patients and non-sarcopenia patients in
the validation cohort. CIR, cumulative incidence of recurrence.
(TIF)
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